droplet-based PCR
Bio-Rad plans to drive adoption of Stilla's all-in-one Nio+ dPCR system while also incorporating its own assays to expand the menu.
The firm expects growth in its ddPCR business this year as it launches new products and the biopharma segment begins to recover from a funding slump.
Bio-Rad Laboratories, Qiagen Settle Digital PCR Patent Dispute
The firms said the settlement in the US District Court of Delaware is pursuant to a global settlement and patent cross-licensing agreement.
Bio-Rad Laboratories, Stilla Technologies Settle IP Lawsuit
Bio-Rad had alleged Stilla's Naica digital PCR system infringed on four patents held or licensed by the firm.
10x Genomics Countersues Bio-Rad Laboratories in Latest Patent Infringement Lawsuit
10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.